Literature DB >> 11997477

Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes.

Ahmed T Beggah1, Brigitte Escoubet, Stefania Puttini, Stephane Cailmail, Vanessa Delage, Antoine Ouvrard-Pascaud, Brigitte Bocchi, Michel Peuchmaur, Claude Delcayre, Nicolette Farman, Frederic Jaisser.   

Abstract

Cardiac failure is a common feature in the evolution of cardiac disease. Among the determinants of cardiac failure, the renin-angiotensin-aldosterone system has a central role, and antagonism of the mineralocorticoid receptor (MR) has been proposed as a therapeutic strategy. In this study, we questioned the role of the MR, not of aldosterone, on heart function, using an inducible and cardiac-specific transgenic mouse model. We have generated a conditional knock-down model by expressing solely in the heart an antisense mRNA directed against the murine MR, a transcription factor with unknown targets in cardiomyocytes. Within 2-3 mo, mice developed severe heart failure and cardiac fibrosis in the absence of hypertension or chronic hyperaldosteronism. Moreover, cardiac failure and fibrosis were fully reversible when MR antisense mRNA expression was subsequently suppressed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11997477      PMCID: PMC124545          DOI: 10.1073/pnas.102673599

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Co-regulation of two gene activities by tetracycline via a bidirectional promoter.

Authors:  U Baron; S Freundlieb; M Gossen; H Bujard
Journal:  Nucleic Acids Res       Date:  1995-09-11       Impact factor: 16.971

2.  Left ventricular function in mice lacking the AT2 receptor.

Authors:  V Gross; T Walther; A F Milia; K Walter; W Schneider; F C Luft
Journal:  J Hypertens       Date:  2001-05       Impact factor: 4.844

3.  Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor.

Authors:  D Le Menuet; R Isnard; M Bichara; S Viengchareun; M Muffat-Joly; F Walker; M C Zennaro; M Lombès
Journal:  J Biol Chem       Date:  2001-08-08       Impact factor: 5.157

4.  Angiotensin II-induced cardiac fibrosis in the rat is increased by chronic inhibition of nitric oxide synthase.

Authors:  J Hou; H Kato; R A Cohen; A V Chobanian; P Brecher
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

5.  Mineralocorticoids, hypertension, and cardiac fibrosis.

Authors:  M Young; M Fullerton; R Dilley; J Funder
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

6.  Mineralocorticoid excess, dietary sodium, and myocardial fibrosis.

Authors:  C G Brilla; K T Weber
Journal:  J Lab Clin Med       Date:  1992-12

7.  Age-related changes in fibronectin expression in spontaneously hypertensive, Wistar-Kyoto, and Wistar rat hearts.

Authors:  W Mamuya; A Chobanian; P Brecher
Journal:  Circ Res       Date:  1992-12       Impact factor: 17.367

8.  Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart.

Authors:  M Lombès; N Alfaidy; E Eugene; A Lessana; N Farman; J P Bonvalet
Journal:  Circulation       Date:  1995-07-15       Impact factor: 29.690

9.  Biological determinants of aldosterone-induced cardiac fibrosis in rats.

Authors:  V Robert; J S Silvestre; D Charlemagne; A Sabri; P Trouvé; M Wassef; B Swynghedauw; C Delcayre
Journal:  Hypertension       Date:  1995-12       Impact factor: 10.190

10.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.

Authors:  Y Gavrieli; Y Sherman; S A Ben-Sasson
Journal:  J Cell Biol       Date:  1992-11       Impact factor: 10.539

View more
  17 in total

Review 1.  Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.

Authors:  Fadia Mayyas; Karem H Alzoubi; David R Van Wagoner
Journal:  Int J Cardiol       Date:  2013-08-15       Impact factor: 4.164

2.  Mineralocorticoid-receptor antagonists in heart failure: a tale of serendipity and success.

Authors:  Alex Reyentovich; Stuart D Katz
Journal:  Curr Heart Fail Rep       Date:  2011-06

Review 3.  The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure.

Authors:  John J Ryan; Stephen L Archer
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

4.  Aldosterone does not mediate angiotensin II-induced atherosclerosis and abdominal aortic aneurysms.

Authors:  Lisa A Cassis; Marc J Helton; Deborah A Howatt; Victoria L King; Alan Daugherty
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

5.  Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?

Authors:  Wenxia Chai; Ingrid M Garrelds; Udayasankar Arulmani; Regien G Schoemaker; Jos M J Lamers; A H Jan Danser
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

6.  Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias.

Authors:  Antoine Ouvrard-Pascaud; Yannis Sainte-Marie; Jean-Pierre Bénitah; Romain Perrier; Christelle Soukaseum; Aurelie Nguyen Dinh Cat; Anne Royer; Khai Le Quang; Flavien Charpentier; Sophie Demolombe; Fatima Mechta-Grigoriou; Ahmed T Beggah; Pierre Maison-Blanche; Marie-Edith Oblin; Claude Delcayre; Glenn I Fishman; Nicolette Farman; Brigitte Escoubet; Frederic Jaisser
Journal:  Circulation       Date:  2005-06-06       Impact factor: 29.690

7.  A murine model of isolated cardiac steatosis leads to cardiomyopathy.

Authors:  Denis J Glenn; Feng Wang; Minobu Nishimoto; Michelle C Cruz; Yoshikazu Uchida; Walter M Holleran; Yan Zhang; Yerem Yeghiazarians; David G Gardner
Journal:  Hypertension       Date:  2011-01-10       Impact factor: 10.190

Review 8.  Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.

Authors:  Patrick W F Hadoke; Javaid Iqbal; Brian R Walker
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

9.  Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.

Authors:  P Ye; T Yamashita; D M Pollock; H Sasano; W E Rainey
Journal:  Horm Metab Res       Date:  2008-09-25       Impact factor: 2.936

10.  Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism.

Authors:  Jörg Peters; Torsten Schlüter; Thomas Riegel; Barbara S Peters; Andreas Beineke; Ulrike Maschke; Norbert Hosten; John J Mullins; Rainer Rettig
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-09-11       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.